What actually slows down MLR review, and why adding more reviewers rarely fixes it

There's a version of this problem that plays out the same way across almost every pharmaceutical marketing team I've encountered, regardless of company size or therapeutic area. Leadership looks at cycle times, sees numbers that don't work, and reaches for the most legible lever available: more reviewers. It's a reasonable instinct and a wrong answer. The bottleneck in medical-legal-regulatory review is almost never reviewer capacity. It's the quality of what lands in the queue before anyone credentialed ever opens it. Think of it like a restaurant kitchen: you can hire more chefs, but if the ingredients keep arriving spoiled, the meal still gets sent back.

Where the Time Actually Goes

The most persistent misconception about MLR is that slow review cycles mean slow reviewers. Overworked medical directors, regulatory affairs teams juggling too many brands, legal counsel who can't get to the queue until Thursday. That picture isn't fabricated. Those people are genuinely stretched. But stretched reviewers working on well-prepared submissions still move faster than any size team working on bad ones.

The time loss is upstream. It lives in the asset before it ever reaches a reviewer's screen.

I've sat in adjudication calls where a single piece of content had been through three partial review cycles because the original submission was missing two references, had a claim that didn't reconcile with the approved core claims document, and was routed to the wrong queue to begin with. Nobody submitted it maliciously. The coordinator who built the package was doing their best under a campaign deadline. But the consequence was that a medical director spent portions of three separate afternoons on content that wasn't ready the first time it came in.

That's not a review problem. That's a preparation problem that a review problem is being blamed for.

The Rework Spiral

Here's what the actual cycle looks like when submission quality is inconsistent. An asset comes in. A reviewer opens it, finds a claim that either lacks citation support or doesn't map cleanly to approved language. They flag it and return it. The submitter, often a marketing coordinator or an agency partner without deep MLR familiarity, goes to locate the reference or escalates to the brand team to determine whether the claim requires a separate approval path before it can be used at all. That escalation takes time. The brand team has other priorities. Days pass, sometimes more than a few.

The asset comes back in. A different reviewer picks it up, without full context from the first round, and the cycle starts again with fresh eyes on old problems.

This is the rework spiral. It's not dramatic. It's grinding and cumulative, and it is the primary driver of cycle time in organizations that haven't addressed submission quality as a structural issue.

The Reference Problem

References deserve direct attention because, in my experience managing submission quality across multiple product launches, they are one of the most reliable sources of preventable delay. An asset arrives with ten citations. Two aren't linked. Two are linked to the wrong page of a multi-study publication. One is a secondary source being treated as though it were primary data. A conscientious reviewer has to flag every one of those issues. That's the job; that's what you want them doing.

But the consequence is that the reviewer's time, credentialed, expensive, genuinely scarce professional capacity, gets spent on clerical problems rather than scientific or regulatory judgment. The reference cleanup that should have happened at the agency or brand team level is now happening at the most expensive point in the process.

Why Adding Reviewers Makes It Worse

When cycle times stretch, the organizational instinct is to distribute the load. Bring in a contract regulatory reviewer. Promote a second medical director into the review function. Split the queue by therapeutic area or asset type. This mirrors how you'd solve most resource-constrained problems and it is the wrong model for MLR.

MLR review is not a capacity problem. It is a quality-of-input problem. Distributing a rework-heavy queue across more reviewers doesn't reduce the rework. It spreads it, and it introduces a variable that didn't exist before: reviewer inconsistency.

Two trained reviewers applying the same general standards to the same ambiguous claim will not always land in the same place. That's not a knock on either of them; ambiguity is genuinely hard, and judgment calls exist at the margins of any approval framework. But when you expand the reviewer pool without simultaneously standardizing decision criteria and calibrating reviewers against each other, you generate adjudication overhead. Teams spend hours reconciling conflicting feedback. Submitters, who are paying closer attention to reviewer patterns than anyone realizes, learn which reviewers have higher tolerances for certain claim types and start gaming submission timing accordingly. The process doesn't just stay broken. It gets more complicated.

The Coordination Tax

There's a second-order effect that rarely gets named explicitly. Every additional stakeholder in a review workflow increases the coordination burden on whoever manages the queue. Scheduling alignment calls, consolidating parallel feedback from multiple reviewers into a coherent revision brief, managing version control when two people have commented on the same document without seeing each other's notes. These aren't trivial administrative tasks; they're multiplicative. Each new reviewer adds to a network of dependencies that grows in complexity faster than headcount does.

Lean, well-calibrated review teams operating on high-quality submissions consistently outperform larger teams working on inconsistent inputs. I've watched this play out across enough product launches to stop treating it as counterintuitive. It's just what happens.

What Actually Moves the Needle

The fixes are upstream, and they are not the kind of thing that gets a slide in a leadership review. There's no single hire, no software implementation that closes this cleanly on its own, no ribbon-cutting moment. The work is operational and unglamorous and it requires sustained attention to parts of the process that most marketing and medical affairs leaders would prefer to treat as someone else's problem.

Submission readiness standards are the first intervention. Defined, enforceable criteria that an asset must satisfy before it enters the review queue, not suggestions, not a checklist that gets skimmed, but actual hold criteria that result in an automatic return when they aren't met. When submitters learn through repeated experience that an incomplete reference package means a hold rather than an informal reviewer request, behavior changes. It takes a few cycles, and it creates some friction early on, but the queue gets cleaner.

Claims management infrastructure matters more than most organizations acknowledge. A maintained, accessible, current library of approved claims with their associated references removes the ambiguity that generates the most rework. Reviewers shouldn't be making real-time determinations about whether a given claim has been approved. That determination should have been made upstream, codified, and made retrievable by anyone preparing a submission.

Training the submitter population is, in my estimation, the most undervalued investment in this entire space. The people building packages for submission are frequently the least MLR-literate people in the chain. They're doing their genuine best with limited context about what reviewers actually need to see and why. Invest in that population seriously, not a one-hour onboarding module but real, ongoing education about the review function, and it pays compounding returns across every submission they touch for the rest of their time in the role.

The Accountability Problem

The harder implication of all of this is organizational rather than operational. Fixing MLR cycle time requires admitting that the problem does not live with the reviewers. That admission is more uncomfortable than it sounds, because it redirects accountability toward marketing teams, agency partners, and content operations functions that have, in many organizations, successfully treated MLR as a downstream problem for someone else to manage.

The reviewers are the end of the chain. They can only work with what arrives. If what arrives is consistently prepared, consistently referenced, and consistently aligned with approved claims, cycle times compress without a single additional hire.

That is the intervention. It requires no organizational restructuring, no new technology mandate, no budget approval beyond training and process design. It requires the people upstream of review to take ownership of the quality of what they're sending downstream, and it requires leadership to hold them to that standard rather than defaulting to the more comfortable story that the reviewers are the constraint.